Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
RCT (n=1775) concludes in people with type 2 diabetes and normoalbuminuria, a high-risk score from the urinary proteomic classifier CKD273 was associated with increased risk of progression to microalbuminuria over median of 2.5yrs, and spironolactone did not prevent progression.
Source:
The Lancet Diabetes & Endocrinology
SPS commentary:
In a related editorial, the author discusses the use of non-invasive urinary biomarkers for early diagnosis, disease progression, and response to therapy in people with diabetes.